Huang Jiacai turned around, his gaze landing on the evaluation summary, his face devoid of emotion. "What does Professor Yang an?"
"Professor Yang says that it is worth a try from a dical standpoint, but the procedure must be compliant. He doesn’t want one case to affect the compliance and credibility of the global promotion of K Therapy," Song Zimo replied.
Huang Jiacai nodded; Professor Yang shows reverence for life, adherence to rules, and consideration for the long-term.
"What are the latest movents from the other major players?"
Next to him, Huang Jiahui replied, "Their united delegation has officially sent a letter requesting a eting as soon as possible. The tone is extrely humble, but the specific position is unclear. Additionally, we’ve monitored so subtle shifts in the dical industry dia and analyst reports in Europe and North Arica. Voices are starting to discuss how to make breakthrough therapies more accessible and how to balance corporate social responsibility with innovation returns. It seems to pave the way for the new frawork we might propose. Soone must be guiding this from behind the scenes."
Huang Jiacai’s lips curled into a smile, "It seems soone is accepting reality faster than we imagined and has started acting. That’s a good thing."
He continued, "Dr. Song, Dr. Tang, what do you think is the biggest challenge of the inclusive frawork we propose?"
Tang Shun pondered, "Execution difficulty, the healthcare systems in different countries and regions vary greatly, with complex paynt abilities, regulatory logic, and interest landscapes. Tiered pricing sounds beautiful, but how to accurately distinguish tiers? How to prevent high-price area drugs from flowing into low-price areas? How to deal with the resistance from local traditional interest groups? This requires extrely intricate design and powerful execution capabilities, and we alone are far from enough."
Song Zimo nodded in agreent: "Also, technical support and risk control. K Therapy and X-2 technology operations are complex, requiring a high standard of dical environnts and doctor training. Large-scale promotion must establish a global technology training, quality control, and support system, which is a huge project."
"You’re both right," Huang Jiacai said calmly, "So, what we need is not one or two partners but a network of ecosystem builders. These traditional giants have their local deep cultivation and political and business resources. Even in so erging markets, we need to find vibrant and ambitious local enterprises."
He lightly tapped his finger on the desktop, "Our role should be platform builders, technology standard setters, and core resource providers. We provide technology and so key products, establish fair entry and benefit distribution rules to attract various parties to give their best on this platform, enlarge the market, and bring technology to patients. In the process, Ruixing and Sanbo will gain reasonable R&D returns, technical influence, and most importantly, build an extensive and efficient network embedded deeply into the global healthcare system."
Song Zimo and Tang Shun exchanged glances and saw the shock in each other’s eyes. Huang Jiacai’s ambition was even larger than they imagined. This was not rely selling technology licenses but leading a gradual reconstruction of the global dical supply chain and paynt system.
"Li Gaoyang and BG are examples," Huang Jiacai’s gaze was deep, "We need behemoths like BG to jump in first and accept our rules, even if initially reluctant. Its demonstration effect will be huge, so the opportunity is rare. Now is our best chance; such an opportunity will not co again."
He paused, then spoke slowly, "Rules can’t be broken, but paths can be found. Professor Yang ntioned a dical trial. Then, if BG could leverage all its energy to promote the expansion of K Therapy for specific late-stage cases in the United States through compassionate use or expedited clinical trial approvals? If they could convince the FDA to open a fast track based on Li Gaoyang’s highly representative case?"
Song Zimo’s eyes lit up, "In that case, it’s not us making exceptions, but rather them finding paths within their national policy frawork, and we just respond to qualified applications, taking a stable first step towards the global stage."
"Exactly," Huang Jiacai nodded, "Convey this idea through appropriate channels to John Ansen and Rolf. Let them strive independently. anwhile, inform Professor Yang’s team to prepare technically. Once the path is open, we must ensure the therapy process is flawless. Li Gaoyang being alive and having good results is the strongest advertisent for our technology, and Li Gaoyang himself must stand up to advocate for us."
Tang Shun remarked, "President Huang, you’re achieving multiple goals at once."
Huang Jiacai responded with tranquility yet power, "Li Gaoyang himself gave us an opportunity, we must seize it and strive to shape it into what they dread. Healthcare should not just be business but also welfare. However, doing good deeds requires wisdom and strategy."
"But... wouldn’t this make us seem immoral?" Huang Jiahui asked nearby.
Huang Jiacai laughed, "Morality? It’s civil to speak morality to humans; it’s foolish to speak morality to beasts. We should be civilized people but also smart people. Smart people first discern between humans and beasts."
Tang Shun was shocked by Huang Jiacai’s words; this guy with only a high school diploma indeed had such insights. He had never studied abroad, yet Tang Shun felt he understood how to deal with people like Li Gaoyang better than himself, always hitting their Achilles’ heel in each confrontation.
...
Almost simultaneously, in a suite at a high-end hotel in Nandu.
Rolf finished a tense video eting with Li Gaoyang and the BG board. The eting was filled with intense debates and heavy breaths, but ultimately Li Gaoyang’s weak yet resolute voice overpowered everything:
"Accept it. We have no choice... no, it’s the only wise choice. Negotiate according to Huang Jiacai’s frawork, strive for the best cooperation conditions. This is for BG’s future, a new dical field; we must be among the first to secure a spot, or in ten or twenty years, we’ll be phased out. Historically, countless companies have been eliminated for failing to keep pace with technological advancents."
At this mont, Rolf leaned against the sofa, exhausted, with his eyes closed. His aides quietly processed docunts nearby, preparing materials for a new round of negotiations. They knew that tomorrow’s negotiations would be completely different. They would no longer be high and mighty takers, but bidders needing to prove their value.
Rolf’s phone vibrated with an encrypted ssage from an unknown number. He opened it to find a single line: "Seek a path within the rules, expanded FDA use, or accelerated trials."
The sender was unsigned, but Rolf imdiately understood. It was a ladder and a test, examining BG’s energy and determination in the United States.
He suddenly opened his eyes, "Contact all our forces in Washington, all the dical research institutions and patient advocacy groups we sponsor. Target: push the FDA to approve the expanded compassionate use agreent for K Therapy in the shortest ti for specific late-stage tumor patients, with Mr. Li Gaoyang as the first applicant. Deploy all legitimate resources at any cost."
"Yes, sir!" the secretary heard clearly.
"Should dia and lobbying groups be involved? I’m afraid the power of dical research institutions and patient advocacy groups alone mightn’t suffice." The secretary worried.
Rolf nodded: "They must intervene comprehensively."
"Okay, this requires massive special funding; will the board approve it?" The secretary expressed concern again.
Rolf thought for a while and calmly said, "Release this news to the elders behind BG Group, their opinions are more reliable than the board."
"Will they get involved in this matter?"
"The desire for longevity will make them make the choices we want."
User Comments
0 comments from readers